Publication:
High measures of pre-chemoradiotherapy platelet-to-albumin ratio indicates poor prognosis in locally advanced pancreatic cancer patients

dc.contributor.coauthorKüçük, A.
dc.contributor.coauthorTopkan, E.
dc.contributor.coauthorHaksöyler, V.
dc.contributor.coauthorMertsoylu, H.
dc.contributor.coauthorBesen, A.A.
dc.contributor.coauthorPehlivan, B.
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorSelek, Uğur
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T12:03:22Z
dc.date.issued2022
dc.description.abstractPurpose: in a lack of similar research, we meant to retrospectively investigate the prognostic significance of pre-chemoradiotherapy (C-CRT) platelet-to-albumin ratio (PAR) on the survival results of locally advanced unresectable pancreatic adenocarcinoma (LAPC) patients. Patients and methods: the present analysis included 139 LAPC patients who received C-CRT in total. The utility of pre-C-CRT cutoff(s) reshaping survival data was explored using receiver operating characteristic (ROC) curve analysis. The primary and secondary objectives were the associations between PAR levels and overall survival (OS) and progression-free survival (PFS) outcomes. Results: at a median follow-up of 15.7 months (95% CI: 11.6-19.8), the overall cohort's median and 5-year OS rates were 14.4 months (95% CI: 11.8-17) and 14.7%, respectively, while the corresponding PFS rates were 7.8 months (95% CI: 6.5-9.1) and 11.2%. Because the ROC curve analysis found 4.9 as the optimal PAR cutoff for both OS and PFS [area under the curve (AUC): 75.4%; sensitivity: 72.4%; specificity: 70.3%], we divided the patients into two PAR cohorts: PAR<4.9 (N=60) and PAR>4.9 (N=79). Comparative analysis per PAR group exhibited significantly worse OS (11.2 vs 18.6 months, and 9.8% vs 20.9% at 5 years, P=0.003) and DFS (7 vs 14.3 months, and 7.6% vs 16.2% at 5 years, P=0.001) with PAR>4.9 versus PAR<4.9, respectively. In multivariate analysis, the N0 nodal status, CA 19-9 <= 90 U/mL, and PAR<4.9 were found to be independent predictors of improved OS and PFS. Conclusion: the pre-C-CRT high PAR (>4.9) robustly and independently prognosticated significantly worse OS and PFS results in inoperable LAPC patients who underwent definitive C-CRT.
dc.description.fulltextYES
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipN/A
dc.description.versionPublisher version
dc.description.volume18
dc.identifier.doi10.2147/TCRM.S359553
dc.identifier.eissn1178-203X
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR03651
dc.identifier.quartileQ3
dc.identifier.scopus2-s2.0-85129060403
dc.identifier.urihttps://hdl.handle.net/20.500.14288/1006
dc.identifier.wos790482900008
dc.keywordsConcurrent chemoradiotherapy
dc.keywordsPancreas cancer
dc.keywordsPlatelet-to-albumin ratio
dc.keywordsPrognosis
dc.keywordsSurvival outcomes
dc.language.isoeng
dc.publisherDove Medical Press
dc.relation.grantnoNA
dc.relation.ispartofTherapeutics and Clinical Risk Management
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/10509
dc.subjectHealth care sciences and services
dc.titleHigh measures of pre-chemoradiotherapy platelet-to-albumin ratio indicates poor prognosis in locally advanced pancreatic cancer patients
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorSelek, Uğur
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
10509.pdf
Size:
1.25 MB
Format:
Adobe Portable Document Format